The company
Korro Bio, Inc.
KRRO · Nasdaq
KRRO stood above a rising 150-day average in 9 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 29.5% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 5
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $41.6M
- Insider sales, 12 months
- $11.4M
- Officials’ trades on record
- 0
- Institutions holding
- 103 (+9)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Jean Francois FormelaDirector | sold | 31,888at $14.12 | 14 Sep 2026filed 15 Sep 2026 |
| Jean Francois FormelaDirector | sold | 6,602at $14.12 | 14 Sep 2026filed 15 Sep 2026 |
| Jean Francois FormelaDirector | sold | 8,450at $13.99 | 11 Sep 2026filed 15 Sep 2026 |
| Jean Francois FormelaDirector | sold | 1,750at $13.99 | 11 Sep 2026filed 15 Sep 2026 |
| Oliver DolanSenior Vice President, Finance | sold | 5at $13.72 | 11 Sep 2026filed 14 Sep 2026 |
| Oliver DolanSenior Vice President, Finance | sold | 6at $13.60 | 9 Sep 2026filed 10 Sep 2026 |
| Oliver DolanSenior Vice President, Finance | sold | 7,347at $13.51 | 8 Sep 2026filed 10 Sep 2026 |
| Jean Francois FormelaDirector | sold | 249at $13.96 | 26 Aug 2026filed 28 Aug 2026 |
| Jean Francois FormelaDirector | sold | 51at $13.96 | 26 Aug 2026filed 28 Aug 2026 |
| Jean Francois FormelaDirector | sold | 23,584at $14.00 | 19 Aug 2026filed 21 Aug 2026 |
| Jean Francois FormelaDirector | sold | 4,884at $14.00 | 19 Aug 2026filed 21 Aug 2026 |
| Jean Francois FormelaDirector | sold | 1,775at $13.96 | 11 Aug 2026filed 13 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Lynx1 Capital Management LPunchanged · filed 12 Aug 2026 | 1,538,296$20.3M | 00.0% |
| NEA Management Company, LLCunchanged · filed 14 Aug 2026 | 1,297,893$17.1M | 00.0% |
| Venrock Adviser, LLCunchanged · filed 14 Aug 2026 | 1,009,500$13.3M | 00.0% |
| Atlas Venture Life Science Advisors, LLCreduced · filed 13 Aug 2026 | 962,884$12.7M | -174,265−15.3% |
| Balyasny Asset Management L.P.reduced · filed 14 Aug 2026 | 951,783$12.5M | -88,271−8.5% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 817,621$10.8M | +357,615+77.7% |
| Affinity Asset Advisors, LLCunchanged · filed 13 Aug 2026 | 706,904$9.3M | 00.0% |
| Nantahala Capital Management, LLCunchanged · filed 14 Aug 2026 | 660,036$8.7M | 00.0% |
| ADAGE CAPITAL PARTNERS GP, L.L.C.added · filed 14 Aug 2026 | 540,968$7.1M | +312,568+136.9% |
| ADAR1 Capital Management, LLCunchanged · filed 14 Aug 2026 | 540,054$7.1M | 00.0% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.